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ABSTRACT
Drug repurposing is an effective strategy to identify new uses for existing drugs, providing the quickest possible transition from
bench to bedside. Existing methods for drug repurposing that mainly focus on pre-clinical information may exist translational
issues when applied to human beings. Real world data (RWD), such as electronic health records and insurance claims,
provide information on large cohorts of users for many drugs. Here we present an efficient and easily-customized framework
for generating and testing multiple candidates for drug repurposing using a retrospective analysis of RWDs. Building upon
well-established causal inference and deep learning methods, our framework emulates randomized clinical trials for drugs
present in a large-scale medical claims database. We demonstrate our framework in a case study of coronary artery disease
(CAD) by evaluating the effect of 55 repurposing drug candidates on various disease outcomes. We achieve 6 drug candidates
that significantly improve the CAD outcomes but not have been indicated for treating CAD, paving the way for drug repurposing.
Introduction
Drug repurposing (a.k.a., drug repositioning) is a strategy to
accelerate the drug discovery process by identifying novel
uses for existing approved drugs [1]. The primary advantage
of drug repurposing over traditional drug development is that it
starts from compounds with well-characterized pharmacology
and safety profiles and can significantly reduce the risk of
adverse effects and attrition in clinical phases [2].
While many successful repurposed drugs (e.g., Viagra for
erectile dysfunction) have been discovered serendipitously
[3], computation-based repurposing methods are developed
recently by leveraging structural features of compounds or
proteins [4, 5], genome-wide association study (GWAS) [6],
transcriptional responses [7], and gene expression [8]. These
methods focus primarily on using pre-clinical information.
Unfortunately, the clinical therapeutic effects in humans are
not always consistent with pre-clinical outcomes [9].
In healthcare, real world data (RWD) [10] refers to lon-
gitudinal observational data derived from sources that are
associated with outcomes in a heterogeneous patient popu-
lation in real-world settings, such as patient surveys, elec-
tronic health records (EHRs), and claims and billing activi-
ties. Since RWDs are direct observations from human bodies,
they become a promising source for drug repurposing. Few
researchers have already validated a small number of repur-
posing drug candidates on RWD [11, 12]. However, there are
some limitations with these approaches. First, most studies
are complementary (i.e., the original hypotheses usually come
from other studies). Second, their studied number of repurpos-
ing candidates is limited and unable to proactively generate
de novo repurposing drug candidates.
In this study, we follow protocols of randomized clinical
trial (RCT) design [13], and computationally screen repurpos-
ing candidates for beneficial effect by explicitly emulating
the corresponding clinical trials using RWDs. Considering
the inherent characteristics of RWD (i.e., temporal sequence
data and existing confounding variables [14]), we apply deep
learning and causal inference methodologies to control the
confounders in RWD, and systematically estimate the drug ef-
fects on various disease outcomes. Specifically, the estimated
drug effects are obtained by long short-term memory (LSTM)
[15] and inverse probability of treatment weighting (IPTW)
[16], on MarketScan claims data [17].
As a test case, we apply the proposed drug repurposing
framework to coronary artery disease (CAD) cohorts of mil-
lions of patients and emulate RCTs for multiple drug candi-
dates, estimating their effects on CAD progression outcomes.
In general, our contributions are three folds:
• We develop a framework for high-throughput screen-
ing of on-marked drugs by emulating, for each drug,
an RCT that evaluates its beneficial effect. The repur-
posed drug candidates can be proactively generated on
existing large-scale RWDs.
• We present an innovative study design for the estima-
tion of the drug’s effect from longitudinal observational
data. The study CAD cohorts are automatically derived
under our framework, which accelerates the process of
computational drug repurposing.
• We propose a deep learning based propensity score esti-
mation model to correct for confounding and selection
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biases. Experimental comparisons to the logistic re-
gression based propensity score estimation model show
that our proposed deep learning model effectively esti-
mate drug effects from RWDs, paving the way for drug
repurposing.
Overall framework
We develop a high throughput computational drug repurpos-
ing pipeline (Fig. 1) that, given a disease cohort (i.e., CAD
patients) extracts a list of potential repurposing drug ingre-
dients and, for each, identifies the corresponding user and
non-user sub-cohorts. It then computes, for all patients in
both sub-cohorts, a large number of features (confounding
factors), as well as the disease progression outcomes. The
treatment effects are estimated after correcting for confound-
ing and selection biases using the deep learning framework
(Fig. 2). Here, the proposed framework is equipped with
attention mechanism that provides the interpretability of the
model. The drug ingredients with beneficial effect and sta-
tistical significance will be considered as repurposed drug
candidates and suggested to be used for treating CAD. Algo-
rithm 1 overviews the steps of estimating the effect of assigned
treatment on the outcome from observational data.
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Figure 1. Flowchart of overall drug repurposing framework.
Results
In this section, we first introduce the dataset we use for this
study. Then we demonstrate the performance of our model
in CAD drug repurposing experiments. We identify more
than 90 million patients in MarketScan [17] data from 2012 to
2017, which contain individual-level, de-identified healthcare
claims information from employers, health plans, hospitals,
Medicare, and Medicaid programs. MarketScan claims data
is primarily used for evaluating health utilization and services.
The overall patients’ distribution of the recording period is
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Figure 2. Illustration of the deep learning model for
predicting treatment probability (a.k.a., propensity score) that
used for correcting confounding from temporal time
sequence data (including diagnoses dt , prescriptions pt and
demographics bt ). It consists of three main components:
embedding module, recurrent neural network and prediction
module.
shown in Fig. 3(a). We take both inpatient and outpatient
claims into consideration. CAD cohort criteria are defined
using International Classification of Diseases (ICD) codes
[18] (Supplementary Table 1 for definitions). In total, there
are 1,178,997 CAD patients. We refer to the first date when
patients were determined to have CAD as CAD initiation date.
Figure 3(b) shows the patients distribution of time before/after
CAD initiation date.
Dataset
We identify three categories of study variables: demographic
characteristics, diagnosis codes and prescription medication.
Demographic characteristics in MarketScan CAD data include
information on age and gender for each patient. Figure 3(d)
shows the age and gender statistics and distribution of our
dataset. Because a majority of data come from commercial
claims, race and ethnicity information is incomplete and is
not included in the analysis. Diagnosis codes in MarketScan
CAD data are defined using the ICD codes for billing purposes.
There are 57,089 ICD-9/10 codes considered in the dataset.
Prescription medications in MarketScan CAD data also con-
tain all prescription drug claims which contain prescription
drug name (generic and brand), national drug code (NDC),
and the number of days of supply approved. By matching
NDC to observational medical outcomes partnership (OMOP)
ingredient concept ID [19], we get 1,353 unique drugs in the
dataset for drug repositioning screening. For drugs with multi-
ple ingredients, we consider each active ingredient separately
in the mapping processes.
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Algorithm 1 The algorithmic framework to estimate effect of
assigned treatment on the outcomes
Input: patient data: assigned treatment, outcomes, values for
potential confounders
Output: repurposed drug candidates, and their estimated
effect, unbalanced feature ratio and significance
1: Generate user and non-user sub-cohorts for the treatment
2: Compute balancing weights for all patients in both sub-
cohorts via LSTM based IPTW
3: Estimate the effect over multiple outcomes after correct-
ing for the biases in the confounders (Eq. (1))
4: Compute the unbalanced feature ratio for the treatment
after re-weighting using standardized difference (Eq. (2))
5: Estimate the significance of effect and compute adjusted
p-value using bootstrapping
6: if estimated effect < 0 and adjusted p-value < 0.05 and
unbalanced feature ratio < 2% then
7: return the estimated effect, unbalanced feature ratio
and computed p-value
8: end if
To evaluate the drug effect, we define a set of clinically-
relevant events linked the CAD as the disease outcomes (e.g.,
heart failure onset and stroke onset) after consulting domain
experts. The definition is based on the ICD codes and can
be found in Table 2 and Table 3 of Supplementary Materials.
Since CAD is the major risk factor for both heart failure
[20] and stroke [21], we hypothesize that an effective drug
will lower the risks of CAD patients develop those diseases.
Figure 3(c) demonstrates the time to develop outcomes from
the CAD initiation date. The confounding variables affect
both treatment assignment of patients and an outcome used
in the trial. We consult domain experts to compile a list
of hypothesized confounders for the CAD case study with
respect to the study variables illustrate above: demographics,
co-morbidities (diagnosis codes) and co-prescribed drugs.
Model performance
Evaluation metrics
Treatment effect estimation In this study, we leverage av-
erage treatment effect (ATE) to examine the treatment effect
at the population level, which is defined as
ATE = E(Y1)−E(Y0) (1)
where E(Y1) and E(Y0) are the expected potential treated and
control outcome of the whole population respectively. The val-
ues of ATE are used to determine whether the given treatment
can improve disease outcomes or not.
Testing feature balance We evaluate the performance of
models by measuring features’ balance between the weighted
user and non-user sub-cohorts generated by the IPTW. Given
patient weights from IPTW, we quantify the balance for each
feature using its standardized mean difference (SMD), which
is the difference in the variable means between the two treat-
ment groups, divided by the combined standard deviation. To
be exact, we use the following definition of the standardized
difference,
SMD =
|µuser−µnonuser|√
(s2user+ s2nonuser)/2
(2)
where µuser and µnonuser are the mean in user cohort and
nonuser cohort; s2user and s
2
nonuser are sample variance of vari-
ables in two sub-cohorts. For binary variables, the variance
s2 is calculated by µ(1−µ). We consider a standardized dif-
ference greater than 0.1 as unbalanced [22] and compute the
unbalanced feature ratio (i.e., #unbalanced feature#all features ) before/after
weighting to evaluate the performance of balancing. The user
and non-user sub-cohorts are considered as balanced if their
unbalanced feature ratio is below 2% after weighting.
Confidence intervals and significance of effect We use
the bootstrapping method [23] to calculate the confidence in-
tervals of estimators of E(Y1) and E(Y0), and statistical signif-
icance of ATE. For each candidate ingredient, we repeatedly
generate multiple different control drugs via random sampling
with replacement, and the analysis is repeated in each boot-
strap sample. The 95% confidence interval is then computed
by using the standard normal approximation: ±1.96 times the
estimate of the standard error. The p-value of the effect esti-
mator can be computed by the normal cumulative distribution
function of estimators. We further use adjusted p-value [24]
as a statistically significant measurement. We consider a re-
purposing drug candidate as significant if its adjusted p-value
is below 0.05.
Performance over repurposing drug candidates
We identify 55 ingredients as drug repurposing candidates
following the study design (see Methods). Then we estimate
the treatment effect on various disease outcomes (i.e., heart
failure and stroke) and demonstrate the distribution of ATE
in Fig. 4. Here, we only show the drug candidates with the
balanced user and non-user sub-cohorts after re-weighting and
statistically significant estimates (adjusted p-value). All the
drugs are ranked from the left side to the right side according
to the increasing order of estimated ATE values. Based on
the definition of ATE (i.e., the weighted average of observed
outcomes from the user and non-user sub-cohorts), the drug
ingredients with ATE values that smaller than 0 are identified
to improve the disease outcomes, while the drug ingredients
with ATE values larger than 0 are identified to worsen the dis-
ease outcomes. For the drugs with beneficial effects, we color
those with known CAD indication in red and those without
known CAD indication in blue (The drug label information is
collected from SIDER [25] database and DrugBank [26]).
From the results, we observe that 9 drugs yield a benefi-
cial effect on disease outcomes among 16 selected significant
drug candidates. Specifically, only 3 drugs have been used
as CAD indication according to their drug labels informa-
tion. The remaining 6 drugs which have not been indicated
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Figure 3. CAD cohorts characteristics. Figure 3(a) shows the patients’ distribution of total time in the database. Figure 3(b)
shows the patients distribution of time before/after CAD initiation date. Figure 3(c) shows the growth of the number of patients
develop outcomes after CAD initiation date. Figure 3(d) shows the gender distribution with age at CAD initiation date.
for treating CAD but can improve the disease outcomes are
considered as repurposed drug candidates. We find evidence
support for these 6 drug candidates from related literature
and web resources as follows: (1) Metoprolol is one of the
most commonly used beta-blockers for treating high blood
pressure and chest pain. It shows beneficial effects in patients
with heart failure associated with CAD [27]; (2) Fenofibrate
is mainly used to treat abnormal blood lipid levels and also
appears to decrease the risk of CAD in patients with diabetes
mellitus [28]; (3) Hydrochlorothiazide which is often used
to treat high blood pressure and diabetes insipidus [29], has
already completed phase 4 trials for CAD treatment [30]; (4)
Pravastatin has also been studied to have a beneficial effect
on CAD [31]; (5) For simvastatin, results from randomized
clinical trials show that it can reduce the occurrence of heart
failure in patients with CAD [32]; (6) Valsartan, a kind of
angiotensin receptor blocker, results in improved coronary
micro-vascular flow reserve, suggesting direct beneficial in
hypertensive patients with stable CAD [33].
We further list the sub-cohort size, feature balancing and
estimated ATE values for each drug candidate in Table. 1.
The results of all 55 drugs can be found in Table 4 of Supple-
mentary Materials. The first column lists the drug names
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Figure 4. Distribution of estimated ATE of drugs on defined
outcomes across the 50 bootstrap samples. All these showing
drugs satisfy two conditions: adjusted p value≤0.05 and post
unbalanced ratio≤ 2%. Within the boxplot, the central line
denotes the median, and the bottom and the top edges denote
the 25th(Q1) and 75th(Q3) and percentiles respectively. The
whiskers extend to 1.5 times the interquartile range.
corresponding to drugs in Fig. 4. The second and third
columns denote the number of patients in user and non-user
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Table 1. Sub-cohorts size, feature balancing and estimated effects for CAD over balanced and statistically significant drug
ingredients. Bold in the table denotes the ingredients without known CAD indication (repurposed drug candidates).
# drug_name # user # non-user
pre.unbalanced
covariates
post.unbalanced
covariates
# covariates
post.unbalanced.ratio
%
pre.ATE post.ATE
metoprolol 9730 29190 38.308 23.231 1270 1.8 -0.023 -0.043
fenofibrate 1352 4056 39.340 13.200 1038 1.3 -0.051 -0.038
rosuvastatin 2420 7260 24.020 9.620 1097 0.9 -0.063 -0.030
hydrochlorothiazide 2001 6003 32.500 15.320 1076 1.4 -0.055 -0.029
amlodipine 4613 13839 21.340 8.300 1180 0.7 -0.050 -0.026
pravastatin 2007 6021 11.260 9.640 1085 0.9 -0.016 -0.022
simvastatin 1605 4815 10.060 13.240 1044 1.3 -0.032 -0.020
valsartan 1316 3948 24.940 13.740 1026 1.3 0.010 -0.015
diltiazem 1044 3132 28.360 13.080 1007 1.3 -0.010 -0.013
isosorbide 1482 4446 33.320 9.560 1039 0.9 0.045 0.034
prasugrel 1316 3948 41.500 18.340 1019 1.8 -0.043 0.036
ramipril 887 2661 25.340 14.840 973 1.5 0.020 0.043
potassium chloride 1110 3330 43.460 20.240 1016 2.0 0.169 0.090
carvedilol 3959 11877 38.280 8.140 1154 0.7 0.198 0.124
furosemide 1545 4635 50.880 17.080 1064 1.6 0.301 0.179
spironolactone 1292 3876 70.620 12.920 1034 1.3 0.393 0.190
sub-cohorts, respectively. The next two columns denote the
average number of unbalanced covariates before and after
re-weighting. The "post unbalanced ratio" column represents
the percentage of unbalanced covariates after re-weighting
(i.e., the number of unbalanced covariates divided by the to-
tal number of covariates). And the last two columns are the
estimated ATE before and after re-weighting. We rank the
drugs by increasing of re-weighted ATE values. We see that
our proposed method successfully corrects for most biases in
the original data which results in a decrease in the number of
unbalanced covariates.
Case studies: attention visualization
Having presented that our model successfully identified repur-
posed drug candidates for CAD treatment, we further demon-
strate the interpretability of our framework achieves via at-
tention mechanism. To exemplify this, we select two case
drug candidates: diltiazem and fenofibrate. According to Ta-
ble. 1, diltiazem and fenofibrate both have beneficial effet
on CAD disease outcomes. Diltiazem has already been used
for treating CAD [34], while fenofibrate does not have CAD
indication on its drug label.
We want to identify the covariates that significantly biased
between the user and non-user cohorts in original data but
balanced after re-weighting. The learned attention weights
enable visualization of each covariate and its SMD values
before/after balancing between user and non-user cohorts. We
select the top 20 well-balanced (i.e., large deviations of SMD
during balancing) covariates and plot the distribution of SMD
values for two case drugs in Fig. 5. The original unweighted
data are denoted in blue dots and LSTM weighted data are in
orange dots. The covariates are ordered from bottom to top
according to the increase of differences between SMD values
of unweighted data and LSTM weighted data. According to
the figure, we see that for both two drugs, the SMD values
in original data are greater than 0.1 (i.e., the threshold of
balancing), which indicates that the original observational
data is highly biased and exists much confounding variables.
The maximum SMD value is about 0.6 for diltiazem and 0.35
for fenofibrate. While the SMD values estimated in the LSTM
weighted data are smaller than 0.1, which means that no major
biases between user and non-user cohort in terms of selected
covariates. The selected covariates include demographics
(e.g., age), co-prescribed drugs (metformin, metoprolol, etc.)
and co-morbidities (e.g., acute myocardial infarction, cardiac
dysrhythmias, etc.). After correcting for these confounding
variables, we can have a more accurate estimation of the
treatment effect on the diseases.
Discussion
In this study, we present a computational drug repurposing
framework for high-throughput screening of on-marked drugs
by emulating a corresponding RCT for each drug and eval-
uating its treatment effect on various disease outcomes. We
propose a deep learning based propensity score model for
correcting selection biases and confounding in longitudinal
observational data. We demonstrate our framework in a case
study of CAD and evaluate 55 different repurposing drug can-
didates on two disease outcomes. According to the results,
we obtain 6 drug candidates (i.e., metoprolol, fenofibrate,
hydrochlorothiazide, pravastatin, simvastatin, valsartan) that
improve the CAD outcomes with statistical significance but
have not been indicated for treating CAD.
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Figure 5. The SMD values of top 20 well balanced covariates. Fig. 5(a) shows results of diltiazem. Fig. 5(b) shows results of
fenofibrate.
We also develop a base version of our model that uses
logistic regression (LR) for computing propensity score and
treatment effect estimation. We conduct comparison experi-
ments on the base model (LR-IPTW) and our model (LSTM-
IPTW) on the above two case drugs and show the results for
diltiazem in Fig. 6 (The results for fenofibrate can be found
in Supplementary Materials).
As the feature balancing is one of the most important eval-
uation metrics, we first plot the distribution of absolute SMD
values computed by LSTM-IPTW and LR-IPTW in Fig. 6(a)
and Fig. 6(d). In both LSTM weighted data and LR weighted
data, many features exhibit large absolute SMD values (greater
than 0.1) in the original data, while most features exhibit low
absolute SMD (below 0.1) after re-weighting. Specifically,
less features exhibit absolute SMD values above 0.1 threshold
after weighted by LSTM model than weighted by LR model.
This indicates that the data is well-balanced by LSTM-IPTW
and the estimated ATE from LSTM-IPTW should be more
accurate than LR-IPTW. Figure 6(b) and Figure 6(e) show the
propensity distribution plot over user and non-user cohorts
using LSTM-IPTW and LR-IPTW models. We observe that
the propensity distribution of LSTM-IPTW is more smooth
(i.e., the propensities are normally distributed) than the dis-
tribution of LR-IPTW. Under LR-IPTW model, many of the
patients in non-user cohorts are predicted to have a propensity
of 0. We also evaluated our models using conventional metrics.
The ROC curve is a standard metric widely used to estimate
the performance of prediction models. The area under ROC
curve (AUC) characterize the accuracy of the prediction re-
sults. Figure 6(c) and Figure 6(f) show the ROC curves for
LSTM-IPTW model and LR-IPTW model. The "Propensity"
curves in the figures are the standard ROC curves of LSTM
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Figure 6. Performance comparison of LSTM-IPTW and LR-IPTW using drug candidate: diltiazem (with known CAD
indication). The three figures on the top are results obtained from LSTM-IPTW, while the figures on the bottom are from
LR-IPTW. Figure 6(a) and Figure 6(d) show the absolute SMD of each covariate in the original data (orange triangles) and in
the weighted data (blue circles). Figure 6(b) and Figure 6(e) show the distribution of estimated propensity scores over user
(orange area) and non-user (blue area) cohorts. Figure 6(c) and Figure 6(f) show the ROC curves for the propensity model
(orange), expected value (green) and weighted propensity (blue).
model and LR model. By comparing the AUC values of two
models, we see that LSTM model yields more accurate predic-
tion results than the LR model. With the accurate treatment
predictions, the model would generate better weights for bal-
ancing and treatment effect estimates in the following tasks.
Besides the standard ROC curve, we also show another two
curves: weighted propensity curve and expected curve. The
weighted propensity curve is obtained by re-weighting the
standard ROC curve using the weights drawn from the propen-
sity model (the same weights applied in covariates balancing
and effect estimates). This curve should be very close to the
curve that would arise by a random assignment (i.e., with an
AUC close to 0.5) which indicates our assumption that the
weighting can emulate an RCT. From the plots, we can find
that LSTM-IPTW performs better than LR-IPTW in terms of
more close value to 0.5. Compared to the standard propensity
ROC curve, "Expected" ROC curve duplicates the population
and assign weights to each individual based on the propensity.
In this setting, each patient contributes their propensity to
the true positives and (1−propensity) to the false positives.
The standard propensity ROC curve should be close to the
expected propensity ROC. We observe that LSTM-IPTW’s
"Propensity" curve is much close to its "Expected" curve when
compared to LR-ITPW.
This study can be extended in multiple directions in the
future. For the study, we use the hypothesized confounders
including demographics, co-morbidities and co-prescribed
drugs. Some other potential confounders such as time elapsed
from the first disease diagnosis to index date and outcome
value calculated over the baseline period could be consid-
ered to build the model in the future work. Also, we can
consider drug combinations and estimate the effect of entire
combinations on the disease outcomes.
In summary, we demonstrate that the proposed computa-
tional drug repurposing framework can successfully identify
drug candidates that have a beneficial effect on disease out-
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comes but not have been indicated for CAD patients yet. The
new LSTM-IPTW model shows better performance for cor-
recting biases and estimating treatment effect than LR-IPTW,
and remaining the interpretability for recognizing significant
confounding.
Methods
In this section, we first introduce the study design, which
includes definitions of cohorts and study variables. Then we
illustrate our deep learning model with three main components
in detail.
Study design
Our framework identifies drug repurposing candidates using
MarketScan CAD data to emulate a bulk of corresponding
RCTs. Below we describe the design of the emulated trials
and the key components of our framework for CAD drug
repurposing.
User and non-user cohorts
Given the drug tested in trial, a patient is assigned to the user
cohort if the following inclusion criteria are satisfied: (1) the
patient has persistently prescribed the drug (e.g., the interval
between two prescriptions is less than 30 days); (2) the patient
is eligible for trial at the time of the first prescription for
the drug. In the CAD study, this condition is that the first
prescription is after CAD initiation data; (3) the patient had a
history in the database of at least one year (365 days) prior to
the first prescription of the drug.
Estimating the effect of a drug requires comparing the
user cohort to a control group assigned with alternative drugs.
Once the alternative drugs are determined, the non-user co-
hort is defined by the same inclusion criteria described above
– but with respect to the alternative drugs. To avoid overlap
between the user and non-user cohorts, the framework further
excludes from the non-user cohort any patient prescribed with
the trial’s drug. In our study design, alternative drugs are
selected randomly from the prescribed ingredients, excluding
the trial drug itself. Such a control group directly compares
the trial’s drug to drugs of the same therapeutic indication, re-
ducing confounding by indication. We use the term index-date
to refer to the date of the first prescription of the assigned drug,
that is, the first time the trial’s drug (respectively, the alterna-
tive drug) was prescribed for patients in the user (respectively,
non-user) cohort.
Baseline and follow-up periods
We refer to the time period prior to the index-date for which
we have information on the patient as the baseline period.
We use the baseline period for characterizing the patients
prior to the beginning of the treatment with the assigned drug.
The follow-up period starts at the index-date, that is, at the
beginning of the treatment with the trial’s drug in the user
cohort, and the control-drug in the non-user cohort. The effect
of the drug is evaluated during the follow-up period. In the
CAD study, the baseline period is at least 365 days, and the
follow-up period is 2 years (730 days). Figure. 7 demonstrates
the definition of user and non-user cohorts.
Baseline period (>= 365 days)
User cohort
 Index data
  trail's drug 1st prescription
Non-user cohort
Patient's data
start-date
CAD	
initiation	date
 Index data
 alternative drug 1st prescription
Follow-up period (730 days)
Follow-up period (730 days)
drugs have been persistently
prescribed (interval < 30 days)
Figure 7. The definition of user and non-user cohorts
Outcomes and hypothesized confounders
The effect of the drug during the follow-up period is defined
with respect to various disease outcomes. In this CAD drug
repurposing case study, we consult domain experts to define
a set of clinically-relevant events linked with CAD as the
outcome, e.g., heart failure onset (Supplemental Table 2) and
stroke onset (Supplemental Table 3). The treatment effect is
estimated on these outcomes during the follow-up period (i.e.,
730 days after index-date). The patient is considered to have
the disease outcome if either of them happens in follow-up
period.
Confounders are variables affecting both treatment as-
signment of patients and an outcome used in the trial, thus
creating a "backdoor path" that may hinder the true effect
of the drug on the outcome. We consult domain experts to
compile a list of hypothesized confounders for the CAD study,
including demographics (e.g., age at the index date, sex), co-
morbidities (e.g., indicator per each ICD-9/10 diagnosis class)
and co-prescribed drugs. Since confounders affect treatment
assignment, they are computed on the baseline period.
Repurposing drug ingredients
We regard a drug as a repurposing candidate if it satisfies
the following condition: (1) an active ingredient (i.e., the
ingredient directly involved in achieving the mediation objec-
tives). (2) persistently prescribed to a large enough number
of patients in the disease cohort. Specifically, an ingredient is
considered being used by a patient only if it was prescribed in
two or more distinct dates, as least one month apart. And a
minimum of 500 patients prescribed a certain ingredient was
required. For each repurposing candidate, we can compute
the user and non-user cohorts according to the above defini-
tion of cohorts. After obtaining the corresponding user and
non-user cohorts, we can extract outcomes and hypothesized
confounders for each individual patient from the database. Ev-
ery patient in their sub-cohort is represented by a sequence of
events, with each event providing the patient information (i.e.,
co-morbidities, co-prescribed drugs, etc.) that corresponds to
each visit. The available data within these visits during the
baseline period, combined with demographic characteristics
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(i.e., age and gender collected at CAD initiation date) are used
as input to the model.
Model
Estimation of average treatment effect
Our proposed framework evaluates the effect of a certain drug
(i.e., trial’s drug) on a clinical outcome with respect to alterna-
tive treatments. Let α = 1 denote the treatment corresponding
to the trial’s drug, and α = 0 denote the alternative treatments.
We define average treatment effect (ATE) of a drug on the
potential outcome Y as ATE = E(Y1)−E(Y0), with E(Yα)
denoting the potential expected prevalence of patients that
would have experienced an outcome event during a complete
follow-up period if all patients in the trial had been assigned
with treatment α . The potential outcomes are referred as coun-
terfactual as only one of these is observed for any given indi-
vidual. By running RCT, we can measure the outcomes within
user and non-user groups into which individuals are randomly
assigned: E(Y1) can be directly estimated as E(Y |α = 1) and
E(Y0) as E(Y |α = 0). However, in observational data (e.g.,
our MarketScan CAD data), treatment assignment is usually
far from being random, which may depend on confounders
(affecting both treatment assignment and outcome). We need
to assign weights to the individuals in each group to avoid the
influence of confounders.
In order to control the influence of confounders, we apply
inverse probability of treatment weighting (IPTW) to create a
pseudo-population from the original one by assigning a weight
wαi to an individual i with treatment α . The weight is defined
as the inverse of conditional probability (aka propensity score)
that an individual is treated with α given the confounding
values. One common issue with IPTW is that individuals
with a propensity score very close to 0 will end up with an
extremely high weight, potentially making the weighted es-
timator unstable. We address this problem by adopting an
alternative weighting function called standardized IPTW [22],
which uses the marginal probability of treatment instead of 1
in the weight numerator.
For estimating the propensity score, logistic regression is
the most popular method in statistics [35, 36]. In longitudinal
observational data, those observational covariates are not a set
of static feature vectors (one for each patient), but irregularly
sampled time series (recording diagnoses, medications, etc.
at each timestamp). Thus, logistic regression is not ideal for
effectively modeling longitudinal observational data.
Model for propensity score weighting
The schematic view of our model is shown in Figure 2, which
consists of three main components: embedding module, re-
current neural network and prediction module. Briefly, the
model estimates the propensity score by first transforming the
input features using an embedding layer. These embedded
features are then fed into LSTM, the output of which at every
time point is aggregated through an attention layer for auto-
matically focusing on important time points. The aggregated
features are fed into a prediction module that provides the
probability of receiving treatment. Each of these is discussed
below in detail.
Embedding module
The embedding module is to convert the initial high-dimensional
and sparse input features into a lower-dimensional and con-
tinuous data representations, which is beneficial to the fol-
lowing prediction task. As shown in Fig. 2, the input fea-
tures are consist of three components: diagnosis, prescrip-
tion and demographic information (age and gender). The
diagnosis codes for each patient at each timestamp can be
denoted as {d1,d2, ...,dt}, and prescription can be denoted
as {p1,p2, ...,pt}. Here, dt and pt are both one dimensional
binary vector with the size of diagnosis code dictionary (r)
and prescription code dictionary (s), respectively. For each
element in the vector, the value one in the j-th column indi-
cates that code j is documented in t-th visit. We use two linear
embedding modules to represent diagnosis and prescription
respectively. That is, we define et = Wdembdt , ft = W
p
embpt ,
where et ∈ Rm denotes the embedding of the input vector
dt ∈ Rr, m the size of the diagnosis embedding dimension,
Wdemb ∈ Rm×r the embedding matrix. ft ∈ Rn denotes the em-
bedding of the input vector pt ∈Rs, n the size of the diagnosis
embedding dimension, Wpemb ∈ Rn×s the embedding matrix.
The age is normalized into range of [0,1] using min-max nor-
malization and the gender is represented as a binary vector.
Having the embedded vectors of patients, we input them to
LSTM.
Recurrent neural network and Attention mechanism
Long short-term memory (LSTM) [15], which is a kind of
recurrent neural network (RNN) equipped with memory cells,
can better model temporality of observational data. LSTM
and its variations are widely adopted in the scenario that
contains sequential and temporal data, such as in language
translation [37], speech recognition [38] and image captioning
[39]. A common LSTM unit contains a cell, an input gate, an
output gate and a forget gate. The cell can remember values
over irregular time intervals and the three gates moderate
the flow of information into and out of the cell. The inputs
to the LSTM are embedded confounding vectors from the
embedding module and the output of which is patient’s latent
health status at the time of visit. We use two LSTMs, LSTMα
and LSTMβ to separately model diagnosis and prescription
codes of patients.
h1,h2, ...,ht = LSTMα(e1,e2, ...,et)
g1,g2, ...,gt = LSTMβ (f1, f2, ..., ft)
(3)
where ht ∈ Ru, gt ∈ Rv are hidden state vectors at t-th visit,
and u,v denote the size of hidden layer of LSTMα and LSTMβ .
Then those patient hidden states are aggregated through two
separate attention layers for automatically focusing on impor-
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tant visits.
αi = Softmax(W>αhi+bα), for i= 1,2..., t
cα =
t
∑
i=1
αihi
βi = Softmax(W>β gi+bβ ), for i= 1,2..., t
cβ =
t
∑
i=1
β igi
(4)
where Wα ∈ Ru, bα ∈ Ru, Wβ ∈ Rv and bβ ∈ Rv are the
parameters to learn. Using the generated attention weights for
diagnosis and prescription, we obtain the aggregated vectors
cα ∈Ru and cβ ∈Rv as defined in Eq. 4. Then we combine cα ,
cβ with vectorized age and gender to predict the probability
of receiving a treatment (propensity score).
Prediction module
The aggregated patient states from attention layer cα ,cβ , com-
bined with the demographic features cdemo, are passed through
a fully-connected neural network predict the probability of
receiving a treatment as follows,
yˆ= Sigmoid(W>ct +b) (5)
where ct = ReLu(Wc[cα ,cβ ,cdemo]+bc), Wc ∈ Rk×(u+v+2),
bc ∈ Rk, W ∈ Rk, b ∈ R are the model parameters. We use
cross-entropy to calculate the prediction loss as follows,
L =− 1
N
N
∑
i=1
(yi log yˆi+(1− yi) log(1− yˆi)) (6)
where yi is the ground truth of observed treatment for patient
i.
Experiment settings
The model is implemented and trained with Python 3.6 and
PyTorch 1.4 1, on a high-performance computing cluster with
four NVIDIA TITAN RTX 6000 GPUs. For each drug candi-
date, we train a model using the adaptive moment estimation
(Adam) algorithm with a batch size of 50 subjects and the
learning rate is 0.001. We run each model for 50 iterations
for computing p-value and confidence interval. We randomly
split the input data into training, validation and test sets with
a ratio of 70%, 10%, 20%. The information from a given
patient is only present in one set. The training set is to train
the proposed models. The validation set is used to improve
the models and select the best model hyperparameters.
Data availability
The access of the MarketScan data analyzed in this manuscript
is provided by The Ohio State University. The dataset may be
available from IBM at https://www.ibm.com/products/
marketscan-research-databases.
1https://pytorch.org/
Code availability
The code for this paper is available at https://github.
com/ruoqi-liu/DeepIPW
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